Inspire Medical Systems, Inc. (INSP) is facing a significant downturn, with shares plummeting over 20% in premarket trading following disappointing first-quarter results that revealed a net loss of $11.29 million. The company also revised its full-year 2026 revenue guidance downward, now projecting between $825 million and $875 million, a notable decrease from the previous estimate of $950 million to $1 billion. This adjustment is primarily attributed to disruptions in reimbursement and CPT coding for its Inspire V system, which has impacted approximately 10,000 cases.
The financial implications are stark, as the company’s adjusted operating margin expectations have been slashed to 2% to 4%, down from 6% to 8%. The lowered earnings per share projections further underscore the challenges ahead, with diluted EPS now anticipated in the range of $0.07 to $0.62. Despite these setbacks, CEO Tim Herbert expressed optimism for a return to growth in 2027, contingent on the clinical efficacy of their products.
Market professionals should closely monitor INSP’s recovery trajectory, as the current pricing reflects significant investor pessimism. The stock’s volatility, trading between $48.30 and $163.35 over the past year, suggests potential opportunities for strategic entry points as the company navigates these challenges.
Source: nasdaq.com